Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2025 Feb;104(2):1291-1293.
doi: 10.1007/s00277-025-06184-6. Epub 2025 Feb 12.

Tafasitamab in refractory diffuse large B-cell lymphoma with neurolymphomatosis

João Ricardo Belo Freitas Mendes  1   2 , Laurine Couleur  3 , Chloe Manca  3 , Valérie Frossard  4 , Mitja Nabergoj  5
Affiliations
Case Reports

Tafasitamab in refractory diffuse large B-cell lymphoma with neurolymphomatosis

João Ricardo Belo Freitas Mendes et al. Ann Hematol. 2025 Feb.

Abstract

Peripheral nervous system involvement in lymphoproliferative diseases, often due to direct nerve infiltration (neurolymphomatosis, NL), is mostly seen in aggressive B-cell lymphoma. We report the case of an 88-year-old man with stage IVA DLBCL, who achieved the first complete response after six R-miniCHOP21 cycles. One year post-treatment, he developed severe neurological symptoms, and PET-CT revealed widespread relapse with extensive neural involvement. Treatment with tafasitamab and lenalidomide led to a complete morpho-metabolic remission and full neurological recovery, with minimal side effects. This case underscores for the very first time the efficacy and tolerability of this regimen in treating NL, highlighting its potential for frail patients unfit for more intensive therapies.

Keywords: DLBCL; Lenalidomide; Neurolymphomatosis; Tafasitamab.

PubMed Disclaimer

Conflict of interest statement

Declarations. Competing interests: MN received honoraria for participation in the speaker’s bureau from Incyte. Patient: Informed written consent was obtained from the patient for publication.

Figures

Fig. 1
Fig. 1
(A) 18 F-FDG PET MIP at relapse showing nodal and extra-nodal involvement at relapse. Bold arrow indicates lymph node cluster in the left supraclavicular region with intense hypermetabolism (SUV max 21.1) involving the 6th cervical vertebral body with extension to the left foraminal and spinal canal, left brachial plexus and nerves. (B) 18 F-FDG PET MIP after C9 showing a complete metabolic response
See this image and copyright information in PMC

References

    1. Xu E, Patel A, Wada T, Rubenstein J, Grommes C (2024) The natural history of Neurolymphomatosis. BJC Rep 2(1):34 - PMC - PubMed
    1. Rauschecker AM, Mohan S, Abbott EM, Whitehead MT (2023) Tafasitamab at the blood–brain barrier. Br J Haematol 201(1):154–157 - PubMed
    1. Gan HK, Azad A, Cher L, Mitchell PL, Millward M, Neurolymphomatosis (2010) Diagnosis, management, and outcomes in patients treated with Rituximab. Neuro Oncol 12(2):212–215 - PMC - PubMed
    1. Hamaguchi M, Wada T, Goto K, Itoh K, Nakashima I (2021) A Case Report of secondary neurolymphomatosis showing selective nerve infiltration and massive lumbar Plexus Enlargement. BMC Neurol 21(1):296 - PMC - PubMed
    1. Byun JM, Lee SS, Park MY, Kim SJ, Oh SY, Kim WS (2016) Diagnosis of secondary Peripheral neurolymphomatosis: a Multi-center experience. Blood 128(22):4222 - PubMed

Publication types

MeSH terms

LinkOut - more resources